Conference abstract
Conference abstractPublished 8 Jun 2015
Novel methodology and drug to treat HIV-mycobacterium co-infection
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Human immunodeficiency virus (HIV) infection and Mycobacterium tuberculosis (TB) are responsible for two of major global human infectious diseases. As a result co-infection is common. Thus, improvements in drug access and simplified treatment regimens are needed immediately. One of the key host cells infected by both HIV and TB is the mononuclear phagocyte (macrophage). Therefore, we hypothesized that one way this can be achieved is through nanoformulated drug that ideally would be active against both HIV and TB. We manufactured nano formulations of antibiotics, antiretroviral therapy and Gallium (Ga). The manufactured nanomedicine was used to study the drug uptake and release kinetics by monocytes (MDM) treated with macrophage colony stimulating factor (MCSF). Finally the efficacy study with nanomedicine was done against Mycobacterium smegmatis, HIV and co-infection in macrophages. The nanoparticle (NP) agent enhanced the drug uptake and maintained the drug release. It also inhibited growth of both HIV and mycobacterium in the macrophage separately and while co-infected for up to 15 days following single drug loading. The NP was also found in all compartments of macrophage in subcellular trafficking study. The multi targeted prolonged-acting NP was effective up to 15 days after single drug loading. The subcellular trafficking of NP was determined and the presence of NP in all the compartments confirmed the multi-targeting approach. These results provide a potential new approach to treat HIV-mycobacterial co-infection that could eventually lead to improved clinical outcomes.
Subjects
Infectious DiseasesMicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 8 Jun 2015
Immunorex TM as vaccine approach by its ability to inhibit HIV-1 and co-infecting pathogens: The role of its lipid fraction carrier
Conference abstract · 8 Jun 2015
ImmunorexTM as vaccine approach by its ability to inhibit HIV-1 and co-infecting pathogens : The role of its Lipid fraction carrier
Conference abstract
Changing trends in epidemiology of leishmaniasis in HIV co-infected patients in India
Conference abstract
HIV infection and impaired innate and adaptive immune responses against Mycobacterium tuberculosis
More from this journal
The newest in Virology & Mycology.
Perspective · 3 Apr 2025
Biofilm Formation and Drug Resistance in Viral and Fungal Coinfections
Perspective · 3 Apr 2025
Climate Change and the Evolution of Virulent Viral and Fungal Strains
Commentary · 3 Apr 2025
Next Generation Diagnostics for Rapid Detection of Viruses and Fungi
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalVirology & Mycology
- SubjectInfectious Diseases
- SubjectMicrobiology
- BylineArticles whose byline prints “Prabagaran Narayanasamy”

